» Articles » PMID: 36844209

Persistence of Inflammatory and Vascular Mediators 5 Months After Hospitalization with COVID-19 Infection

Abstract

Background And Aim: In acute severe COVID-19, patients present with lung inflammation and vascular injury, accompanied by an exaggerated cytokine response. In this study, our aim was to describe the inflammatory and vascular mediator profiles in patients who were previously hospitalized with COVID-19 pneumonitis, months after their recovery, and compare them with those in patients recovering from severe sepsis and in healthy controls.

Methods: A total of 27 different cytokine, chemokine, vascular endothelial injury and angiogenic mediators were measured in the plasma of forty-nine patients 5.0 ± 1.9 (mean ± SD) months after they were hospitalized with COVID-19 pneumonia, eleven patients 5.4 ± 2.9 months after hospitalization with acute severe sepsis, and 18 healthy controls.

Results: Compared with healthy controls, IL-6, TNFα, SAA, CRP, Tie-2, Flt1, and PIGF were significantly increased in the post-COVID group, and IL-7 and bFGF were significantly reduced. While IL-6, PIGF, and CRP were also significantly elevated in post-Sepsis patients compared to controls, the observed differences in TNFα, Tie-2, Flt-1, IL-7 and bFGF were unique to the post-COVID group. TNFα levels significantly correlated with the severity of acute COVID-19 illness (spearman's r = 0.30, < 0.05). Furthermore, in post-COVID patients, IL-6 and CRP were each strongly negatively correlated with gas transfer factor %predicted (spearman's r = -0.51 and r = -0.57, respectively, < 0.002) and positively correlated with computed tomography (CT) abnormality scores at recovery (r = 0.28 and r = 0.46, < 0.05, respectively).

Conclusion: A unique inflammatory and vascular endothelial damage mediator signature is found in plasma months following acute COVID-19 infection. Further research is required to determine its pathophysiological and clinical significance.

Citing Articles

Construction and validation of a risk model of proteinuria in patients with omicron COVID-19: retrospective cohort study.

Teng L, Chang G, Song X, Zhang M, Han Y, Chang W Ren Fail. 2024; 46(2):2365979.

PMID: 39108141 PMC: 11308959. DOI: 10.1080/0886022X.2024.2365979.


Pathogenic mechanisms of cardiovascular damage in COVID-19.

Shao H, Yin R Mol Med. 2024; 30(1):92.

PMID: 38898389 PMC: 11186295. DOI: 10.1186/s10020-024-00855-2.


Unraveling the Underlying Molecular Mechanism of 'Silent Hypoxia' in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway.

Devaux C, Lagier J J Clin Med. 2023; 12(6).

PMID: 36983445 PMC: 10056466. DOI: 10.3390/jcm12062445.

References
1.
Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

2.
. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021; 397(10285):1637-1645. PMC: 8084355. DOI: 10.1016/S0140-6736(21)00676-0. View

3.
Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S . The IL-1β, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med. 2022; 3(6):100663. PMC: 9214726. DOI: 10.1016/j.xcrm.2022.100663. View

4.
Zoufaly A, Poglitsch M, Aberle J, Hoepler W, Seitz T, Traugott M . Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir Med. 2020; 8(11):1154-1158. PMC: 7515587. DOI: 10.1016/S2213-2600(20)30418-5. View

5.
Leisman D, Deutschman C, Legrand M . Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. 2020; 46(6):1105-1108. PMC: 7186535. DOI: 10.1007/s00134-020-06059-6. View